Galimedix Therapeutics

Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease: Galimedix’s initial areas of focus. Its amyloid beta-targeting approach is strongly supported by our license deal with a major ophthalmology player, as well as recent successes in the field of Alzheimer’s disease. Galimedix’s approach blocks a key step in the neurodegenerative process with a highly specific, well tolerated small molecule without impacting normal neuronal function. This key step – the formation of toxic oligomers and protofibrils of amyloid beta (Aβ) – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals and by positive late-stage clinical results with Aβ-targeting therapies for Alzheimer’s disease, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.

Galimedix Therapeutics has raised $2M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include InFocus Capital Partners, Rimonci Capital.

Galimedix Therapeutics was founded in 2017 by Christopher Parsons (Co-Founder, Chief Pharmacologist & VP of Non-Clinical Development), Herman Russ (Co-founder & CSO), Andrew Pearlman (Co-founder & President).

Galimedix Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Galimedix Therapeutics is based in Shorashim, Israel, North District. The company also has offices abroad.